This is already underway for a compound whose corrective effect was observed in cells carrying a mutation responsible
for myotonic dystrophy type I.
The proof of concept of such approach has been initiated in the team on a PGD - derived hES cells carrying the causative mutation
for Myotonic Dystrophy type 1 (DM1).
Not exact matches
Validating this original concept, we previously demonstrated that PGD - derived hES cells and their derivatives, which express the causal mutation implicated in the
Myotonic Dystrophy type 1 (DM1), offer pertinent disease - cell models, applicable
for a wide systemic mechanistic analysis ranging from functional studies at the cellular level to a large - scale drug screening.
For the first time, through the use of human embryonic stem cells (hES) sourced from pre-implantation diagnosis, researchers from Inserm's Institute for Stem Cell Therapy and Exploration of Monogenic Diseases (I - Stem) have successfully identified the previously unknown mechanisms involved in Steinert» disease, also known as type 1 myotonic dystrop
For the first time, through the use of human embryonic stem cells (hES) sourced from pre-implantation diagnosis, researchers from Inserm's Institute
for Stem Cell Therapy and Exploration of Monogenic Diseases (I - Stem) have successfully identified the previously unknown mechanisms involved in Steinert» disease, also known as type 1 myotonic dystrop
for Stem Cell Therapy and Exploration of Monogenic Diseases (I - Stem) have successfully identified the previously unknown mechanisms involved in Steinert» disease, also known as type 1
myotonic dystrophy.
Validating this concept, we previously demonstrated that human pluripotent stem cells and derivatives which, express the causal mutation implicated in the
Myotonic Dystrophy type 1 (DM1), offer pertinent disease - cell models, applicable
for a wide systemic analysis ranging from mechanistic studies to therapeutic screening.
CpG methylation, a parent - of - origin effect
for maternal - biased transmission of congenital
myotonic dystrophy.
Dr. Barbé: The molecular mechanisms responsible
for the onset and severity of repeat diseases, such as
myotonic dystrophy and Huntington's disease, are largely unknown.